European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.

Article  Google Scholar 

Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74:1014–48.

Article  PubMed  Google Scholar 

Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56:593–619.

Article  PubMed  PubMed Central  Google Scholar 

Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–49.

Article  PubMed  Google Scholar 

Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle. 2021;12:1948–58.

Article  PubMed  PubMed Central  Google Scholar 

Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59:474–81.

Article  PubMed  Google Scholar 

Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131–7.

Article  PubMed  Google Scholar 

Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.

Article  CAS  PubMed  Google Scholar 

Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–42.

Article  CAS  PubMed  Google Scholar 

Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3–4 study. Am J Kidney Dis. 2011;57:692–9.

Article  CAS  PubMed  Google Scholar 

Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258–68.

Article  CAS  PubMed  Google Scholar 

Hiramine Y, Uto H, Imamura Y, et al. Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. Hepatol Res. 2017;47:542–57.

Article  CAS  PubMed  Google Scholar 

Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2017;47:854–61.

Article  CAS  PubMed  Google Scholar 

Kogiso T, Yamamoto K, Kobayashi M, et al. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatol Res. 2017;47:835–44.

Article  CAS  PubMed  Google Scholar 

Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatol Res. 2018;48:E311–9.

Article  CAS  PubMed  Google Scholar 

Uojima H, Kinbara T, Hidaka H, et al. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017;47:E14–21.

Article  CAS  PubMed  Google Scholar 

Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256–63.

Article  CAS  PubMed  Google Scholar 

Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS One. 2017;12: e0174649.

Article  PubMed  PubMed Central  Google Scholar 

Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137–46.

Article  CAS  PubMed  Google Scholar 

Nakai M, Suda G, Kubo A, et al. Durable response without recurrence to tolvaptan improves long-term survival. J Gastroenterol. 2020;55:1150–61.

Article  CAS  PubMed  Google Scholar 

Uojima H, Hidaka H, Nakayama T, et al. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: a randomized study. World J Gastroenterol. 2017;23:8062–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barasch J, Mori K. Cell biology: iron thievery. Nature. 2004;432:811–3.

Article  CAS  PubMed  Google Scholar 

Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. The Lancet. 2005;365:1231–8.

Article  CAS  Google Scholar 

Tsuchimoto A, Shinke H, Uesugi M, et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One. 2014;9: e110527.

Article  PubMed  PubMed Central  Google Scholar 

Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol. 2015;62:968–74.

Article  PubMed  Google Scholar 

Ohara M, Suda G, Kimura M, et al. Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol Res. 2020;50:715–25.

Article  CAS  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  CAS  PubMed  Google Scholar 

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

Article  CAS  PubMed  Google Scholar 

Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.

Article  CAS  PubMed  Google Scholar 

Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.

Article  PubMed  Google Scholar 

Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellos I, Kontzoglou K, Perrea DN. Predictors of tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol. 2020;35:182–91.

Article  CAS  PubMed  Google Scholar 

Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–84.

Article  PubMed  Google Scholar 

Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury–where do we stand today? Nephrol Dial Transplant. 2011;26:762–4.

Article  CAS  PubMed  Google Scholar 

Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22:2089–95.

Article  PubMed  Google Scholar 

Liebetrau C, Gaede L, Doerr O, et al. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014;74:81–8.

Article  CAS  PubMed  Google Scholar 

Gomes BC, Silva Junior JM, Tuon FF. Evaluation of urinary NGAL as a diagnostic tool for acute kidney injury in critically ill patients with infection: an original study. Can J Kidney Health Dis. 2020;7:2054358120934215.

Article  PubMed  PubMed Central  Google Scholar 

Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin a